Javascript must be enabled to continue!
Enhanced gene expression from retroviral vectors
View through CrossRef
Abstract
Background
Retroviruses are widely used to transfer genes to mammalian cells efficiently and stably. However, genetic elements required for high-level gene expression are incompatible with standard systems. The retroviral RNA genome is produced by cellular transcription and post-transcriptional processing within packaging cells: Introns present in the retroviral genomic transcript are removed by splicing, while polyadenylation signals lead to the production of ineffective truncated genomes. Furthermore strong enhancer/promoters within the retroviral payload lead to detrimental competition with the retroviral enhancer/promoter.
Results
By exploiting a new method of producing the retroviral genome in vitro it is possible to produce infectious retroviral particles carrying a high-level expression cassette that completely prohibits production of infectious retroviral particles by conventional methods.
We produced an expression cassette comprising a strong enhancer/promoter, an optimised intron, the GFP open reading frame and a strong polyadenylation signal. This cassette was cloned into both a conventional MMLV retroviral vector and a vector designed to allow in vitro transcription of the retroviral genome by T7 RNA polymerase.
When the conventional retroviral vector was transfected into packaging cells, the expression cassette drove strong GFP expression, but no infectious retrovirus was produced. Introduction of the in vitro produced uncapped retroviral genomic transcript into the packaging cells did not lead to any detectable GFP expression. However, infectious retrovirus was easily recovered, and when used to infect target primary human cells led to very high GFP expression – up to 3.5 times greater than conventional retroviral LTR-driven expression.
Conclusion
Retroviral vectors carrying an optimized high-level expression cassette do not produce infectious virions when introduced into packaging cells by transfection of DNA. Infectious retrovirus carrying the same cassette is readily produced when packaging cells are transfected with in vitro transcribed retroviral genomic RNA. The applications of this technique are not limited to producing the higher levels of transgene expression demonstrated here. For example, novel reporters with alternatively spliced exon-intron configurations could readily be transduced into virtually any cell. Furthermore, because the in vitro transcripts are not translated within the packaging cells, retroviruses carrying genes lethal to the packaging cells can also be produced.
Springer Science and Business Media LLC
Title: Enhanced gene expression from retroviral vectors
Description:
Abstract
Background
Retroviruses are widely used to transfer genes to mammalian cells efficiently and stably.
However, genetic elements required for high-level gene expression are incompatible with standard systems.
The retroviral RNA genome is produced by cellular transcription and post-transcriptional processing within packaging cells: Introns present in the retroviral genomic transcript are removed by splicing, while polyadenylation signals lead to the production of ineffective truncated genomes.
Furthermore strong enhancer/promoters within the retroviral payload lead to detrimental competition with the retroviral enhancer/promoter.
Results
By exploiting a new method of producing the retroviral genome in vitro it is possible to produce infectious retroviral particles carrying a high-level expression cassette that completely prohibits production of infectious retroviral particles by conventional methods.
We produced an expression cassette comprising a strong enhancer/promoter, an optimised intron, the GFP open reading frame and a strong polyadenylation signal.
This cassette was cloned into both a conventional MMLV retroviral vector and a vector designed to allow in vitro transcription of the retroviral genome by T7 RNA polymerase.
When the conventional retroviral vector was transfected into packaging cells, the expression cassette drove strong GFP expression, but no infectious retrovirus was produced.
Introduction of the in vitro produced uncapped retroviral genomic transcript into the packaging cells did not lead to any detectable GFP expression.
However, infectious retrovirus was easily recovered, and when used to infect target primary human cells led to very high GFP expression – up to 3.
5 times greater than conventional retroviral LTR-driven expression.
Conclusion
Retroviral vectors carrying an optimized high-level expression cassette do not produce infectious virions when introduced into packaging cells by transfection of DNA.
Infectious retrovirus carrying the same cassette is readily produced when packaging cells are transfected with in vitro transcribed retroviral genomic RNA.
The applications of this technique are not limited to producing the higher levels of transgene expression demonstrated here.
For example, novel reporters with alternatively spliced exon-intron configurations could readily be transduced into virtually any cell.
Furthermore, because the in vitro transcripts are not translated within the packaging cells, retroviruses carrying genes lethal to the packaging cells can also be produced.
Related Results
Improved retroviral suicide gene transfer in colon cancer cell lines after cell synchronization with methotrexate
Improved retroviral suicide gene transfer in colon cancer cell lines after cell synchronization with methotrexate
Abstract
Background
Cancer gene therapy by retroviral vectors is mainly limited by the level of transduction. Retroviral gene transfer requires t...
Expression and polymorphism of genes in gallstones
Expression and polymorphism of genes in gallstones
ABSTRACT
Through the method of clinical case control study, to explore the expression and genetic polymorphism of KLF14 gene (rs4731702 and rs972283) and SR-B1 gene (rs...
The Use of Adeno-associated virus (AAV) in Vaccine Development
The Use of Adeno-associated virus (AAV) in Vaccine Development
Adeno-associated virus (AAV) is a very tiny (20-26 nm) icosahedral and non-enveloped virus, and it belongs to the Parvoviridae family. AAV vectors are the most widely used ...
Fetal liver hematopoietic stem cells as a target for in utero retroviral gene transfer
Fetal liver hematopoietic stem cells as a target for in utero retroviral gene transfer
Retroviral-mediated gene transfer into hematopoietic precursors often results in only short-term gene transduction in vivo. Loss of the transduced genetic material over time may be...
Variants of the vitamin D receptor gene and the expression of microRNA‑21, microRNA‑125a, microRNA‑125b and microRNA‑214 in coronary heart disease
Variants of the vitamin D receptor gene and the expression of microRNA‑21, microRNA‑125a, microRNA‑125b and microRNA‑214 in coronary heart disease
Background. The protective effects of vitamin D in relation to atherogenesis are realized by vitamin D receptors (VDR). Variants rs10735810, rs731236, rs1544410 and rs797532 of the...
Abstract 1836: Global gene expression profiles from bladder tumor FFPE samples
Abstract 1836: Global gene expression profiles from bladder tumor FFPE samples
Abstract
Cancer is a disease characterized by uncontrolled cell growth and proliferation. Recent advances in molecular medicine and cancer biology have changed the w...
Experimental study on pancreatic cancer gene therapy using the HSV‐TK gene mediated by a retroviral vector
Experimental study on pancreatic cancer gene therapy using the HSV‐TK gene mediated by a retroviral vector
OBJECTIVE: To study the value of the herpes simplex virus type I thymidine kinase (HSV‐TK) gene mediated by a retroviral vector in the treatment of human pancreatic cancer cell lin...
Abstract P1-05-23: Utilities and challenges of RNA-Seq based expression and variant calling in a clinical setting
Abstract P1-05-23: Utilities and challenges of RNA-Seq based expression and variant calling in a clinical setting
Abstract
Introduction
Variant calling based on DNA samples has been the gold standard of clinical testing since the advent of Sanger sequencing. The u...

